

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034
CLINICAL BENEFIT	☒ MINIMIZE SAFETY RISK OR CONCERN. ☒ MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. ☐ ASSURE APPROPRIATE LEVEL OF CARE. ☐ ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. ☒ ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. ☐ ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective date:	8/1/2026

POLICY

Vagus Nerve Stimulator

Vagus nerve stimulation may be considered **medically necessary** as a treatment of medically refractory seizures.

Vagus nerve stimulation is considered **investigational** as a treatment of other conditions, including but not limited to depression, heart failure, upper-limb impairment due to stroke, essential tremors, headaches, rheumatoid arthritis, fibromyalgia, tinnitus, and traumatic brain injury as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Transcutaneous (nonimplantable) vagus nerve stimulation devices are considered **investigational** for all indications as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Implantable Peripheral Nerve Stimulator

Peripheral nerve stimulation as a treatment for chronic pain is considered **investigational** as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Restorative neurostimulation therapy (ReActiv8) is considered **investigational** as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Policy Guidelines

Medically refractory seizures are defined as seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels of antiepileptic drugs because of intolerable adverse events of these drugs.

The Nalu Medical, Inc. and Neuspera Medical Inc. device indications state "trial devices are solely for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device."

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

Cross-References:

MP 1.141 Peripheral Subcutaneous Field Stimulation (PSFS)

MP 2.092 Cranial Electrotherapy Stimulation (CES) and Auricular Electrostimulation

MP 6.050 Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)

PRODUCT VARIATIONS

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>.

DESCRIPTION/BACKGROUND

Vagus Nerve Stimulation

Vagus nerve stimulation (VNS) was initially investigated as a treatment alternative in patients with medically refractory partial-onset seizures for whom surgery is not recommended or for whom surgery has failed. Over time, the use of VNS has expanded to include generalized seizures, and it has been investigated for a range of other conditions.

While the mechanisms for the therapeutic effects of VNS are not fully understood, the basic premise of VNS in the treatment of various conditions is that vagal visceral afferents have a diffuse central nervous system projection, and activation of these pathways has a widespread effect on neuronal excitability. An electrical stimulus is applied to axons of the vagus nerve, which have their cell bodies in the nodose and junctional ganglia and synapse on the nucleus of the solitary tract in the brainstem. From the solitary tract nucleus, vagal afferent pathways project to multiple areas of the brain. VNS may also stimulate vagal efferent pathways that innervate the heart, vocal cords, and other laryngeal and pharyngeal muscles, and provide parasympathetic innervation to the gastrointestinal tract.

Other types of implantable vagus nerve stimulators that are placed in contact with the trunks of the vagus nerve at the gastroesophageal junction are not addressed in this evidence review.

Regulatory Status

In Table 1 includes updates on the U.S. Food and Drug Administration (FDA) approval and clearance for VNS devices pertinent to this evidence review.

Table 1. FDA-Approved or -Cleared Vagus Nerve Stimulators (Product Codes: LYJ, MUZ, PKR, QAK, QPY, SFJ)

Device Name	Manufacturer	Cleared	PMA/510(k)	Indications
NeuroCybernetic Prosthesis (NCP®)	LivaNova (Cyberonics)	1997	P970003	Indicated or adjunctive treatment of adults and

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

/ VNS Therapy®; Product Codes LYJ, MUZ				adolescents >12 y of age with medically refractory partial-onset seizures
		2005	P970003/ S50	Expanded indication for adjunctive long-term treatment of chronic or recurrent depression for patients ≥18 y of age experiencing a major depressive episode and have not had an adequate response to ≥4 adequate antidepressant treatments
		2017	P970003/ S207	Expanded indicated use as adjunctive therapy for seizures in patients ≥4 y of age with partial-onset seizures that are refractory to antiepileptic medications
gammaCore®; Product Codes PKR, QAK	ElectroCore	2017/2018	DEN150048/ K171306/ K173442	Indicated for acute treatment of pain associated with episodic cluster headache in adults using noninvasive VNS on the side of the neck
gammaCore-2®, gammaCore- Sapphire®; Product Code PKR	ElectroCore	2017/2018/ 2021	K172270/ K180538/ K182369/ K191830/ K203456/ K211856	Indicated for: Adjunctive use for the preventive treatment of cluster headache in adult patients. The acute treatment of pain associated with episodic cluster headache in adult patients. The acute treatment of pain associated with migraine headache in adult patients.

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

				The preventive treatment of migraine headache in adult patients.
Microtransponder® Vivistim® Paired VNS™ system	Microtransponder Inc.	2021	210007	The device is intended to stimulate the vagus nerve during rehabilitation therapy to reduce upper extremity motor deficits and improve motor function in patients with chronic ischemic stroke and moderate to severe arm impairment.
SetPoint System	SetPoint Medical	2025	P240039	Indicated for use in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response, or intolerance to one or more biologic or targeted synthetic DMARDs

FDA: Food and Drug Administration; PMA: premarket approval; VNS: vagus nerve stimulation

Peripheral Nerve Stimulation

Peripheral nerve stimulation (PNS) has been used to treat chronic pain. It is a system consisting of leads, electrodes, and a pulse transmitter that delivers electrical impulses to peripheral nerves. Leads are placed using ultrasound guidance and can be placed for temporary or permanent use in an outpatient procedure.

Peripheral Nerve Stimulation for Neuropathic Chronic Pain

Chronic, noncancer pain is responsible for a high burden of illness and can be defined as persistent pain that lasts for more than 3 months. Chronic pain of peripheral origin may be caused by damage to peripheral nerves impacting the upper and lower extremities.

Regulatory Status for PNS Devices for Neuropathic Chronic Pain

A number of PNS devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. These are listed in Table 2.

Two PNS devices by Stimwave Technologies Inc., the StimQ Peripheral Nerve Stimulator (PNS) System and the Receiver Kit, Trial Kit, Spare Lead Kit, Sterile Revision Kit, SWAG Kit, SWAG

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

Accessory Kit, Charger Kit, were recalled in Sept 2020 for the product containing a non-functional component not referenced in product labeling.

Table 2. FDA-Cleared Peripheral Nerve Stimulation Devices (FDA Product Codes: GZF, NHI)

Device Name	Manufacturer	Cleared	510(k)	Indications
Nalu Neurostimulation Kit (Integrated, 40 cm: Single 8/Dual 8), Nalu Neurostimulation Kit (Ported, 2 cm: Single 8/Dual 8), Dual 8 Ported Nalu Implantable Pulse Generator with 40 cm Kit, 40 cm/ 60 cm Trial/Extension Lead Kits, Patient Kits and miscellaneous replacement kits	Nalu Medical, Inc.	March 2019	K183579	This system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach. The system is not intended to treat pain in the craniofacial region.
IPG, integrated, 25/40 cm, single, tined, IPG, 2 cm, single 4, Lead (25/40 cm, 4, tined), Extension - 4	Nalu Medical, Inc.	Sept 2019	K191435	This system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The system is not intended to treat pain in the craniofacial region.
StimRouter Neuromodulation System	Bioness, Inc.	Oct 2019, March 2020, Feb 2022	K190047, K200482, K211965	The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

				(e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
Stimulator, Stimulator Kit, External Transmitter, External Transmitter Kit	Micron Medical Corporation	Aug 2020	K200848	Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Moventis PNS is not intended to treat pain in the craniofacial region.
Neuspera Neurostimulation System (NNS)	Neuspera Medical, Inc.	Aug 2021	K202781	The Neuspera Neurostimulation System (NNS) is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach. The system is not intended to treat pain in the craniofacial region.
Neuspera Nuity System	Neuspera Medical, Inc.	April 2023	K221303	The Neuspera Nuity™ System (NNS) is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent or as an

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

				adjunct to other modes of therapy used in a multidisciplinary approach. The system is not intended to treat pain in the craniofacial region.
Freedom Peripheral Nerve Stimulator (PNS) System	Curonix, Inc	June 2024	K233162	The Freedom Peripheral Nerve Stimulator (PNS) System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Freedom Trial Lead Kit is only to be used in conjunction with the Freedom Neurostimulator Kit. The trial devices are solely used for a trial stimulation period (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.
SPRINT Peripheral Nerve Stimulation (PNS)	SPR Therapeutics, Inc	July 2018	K181422	The SPRINT PNS system is indicated for up to 60 days in the back and/or extremities for symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; and symptomatic relief of post-operative pain. This

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

				system is not intended to treat pain in the craniofacial region.
--	--	--	--	--

Restorative Neurostimulation for Chronic Lower Back Pain Attributed to Multifidus Dysfunction

Restorative neuromodulation therapy (ReActiv8) uses an implanted device to deliver electrical stimulation to the nerves controlling the multifidus muscles of the lumbar spine. It is proposed that restorative neuromodulation reduces pain by triggering contractions of the multifidus muscles to restore neuromuscular control and help stabilize the spine. It is intended for individuals with intractable chronic low back pain associated with multifidus dysfunction for whom available low back pain treatments do not provide sufficient or durable symptom relief.

Regulatory Status for Restorative Neurostimulation Devices

In 2020, the ReActiv8 (Mainstay Medical) was FDA approved through the Premarket Approval (PMA) process (PMA P190021) for individuals with intractable chronic low back pain associated with multifidus dysfunction for whom available low back pain treatments do not provide sufficient or durable symptom relief. FDA Product Code: QLK

RATIONALE

Summary of Evidence

Vagus Nerve Stimulation

For individuals who have seizures refractory to medical treatment who receive VNS, the evidence includes RCTs and multiple observational studies. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs have reported significant reductions in seizure frequency for patients with partial-onset seizures. The uncontrolled studies have consistently reported large reductions in a broader range of seizure types in both adults and children. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have treatment-resistant depression who receive VNS, the evidence includes 2 RCTs evaluating the efficacy of implanted VNS for treatment-resistant depression compared to sham, 1 RCT comparing therapeutic to low-dose implanted VNS, nonrandomized comparative studies, and case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The sham controlled RCTs only reported short-term results and found no significant improvement in the primary outcome. The low-dose VNS controlled trial reported no statistically significant differences between the dose groups for change in depression symptom score from baseline. Other available studies are limited by small sample sizes, potential selection

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

and confounding biases, and lack of a control group in the case series. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic heart failure who receive VNS, the evidence includes a systematic review including 4 RCTs and case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Meta-analyses of the RCTs evaluating chronic heart failure found significant improvements in the New York Heart Association functional class, quality of life, 6-minute walk-test, and N-terminal-pro brain natriuretic peptide levels in patients treated with VNS compared to control. An analysis of the ANTHEM-HF uncontrolled trial evaluated longer-term outcomes of VNS use in chronic heart failure. They found that left ventricular (LV) ejection fraction improved by 18.7%, 19.3%, and 34.4% at 12, 24, and 36 months, respectively, with high-intensity VNS. Individuals with low-intensity VNS only had significant improvement in LV ejection fraction at 24 months (12.3%). The ANTHEM-HFpEF trial found improvements in New York Heart Association functional class, quality of life, and 6-minute walk test distances in patients with preserved ejection fraction and implanted VNS. Although this data is promising, a lack of a no-VNS comparator group precludes drawing conclusions based on findings from the uncontrolled studies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have upper-limb impairment due to stroke who receive VNS, the evidence includes 3 pilot RCTs. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Two RCTs compared VNS plus rehabilitation to rehabilitation alone; 1 failed to show significant improvements for the VNS group on response and function outcomes, but the other, which had a larger patient population, found a significant difference in response and function outcomes. The other RCT compared VNS to sham and found that although VNS significantly improved response rate, there were 3 serious adverse events related to surgery. Longer-term follow-up studies are needed to evaluate long-term efficacy and safety. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For adults with moderate-to-severe rheumatoid arthritis who receive VNS, the evidence includes 1 pilot randomized, sham-controlled trial and 1 multicenter sham-controlled RCT. The pilot RCT in multidrug-refractory RA demonstrated procedural feasibility and safety. The trial reported that American College of Rheumatology Score 20 [ACR20] and Disease Activity Score-28 [DAS28] outcomes were numerically superior for the VNS group; however, these differences were not statistically compared, as the study wasn't powered for effectiveness. The pivotal RESET-RA trial was a multicenter, double-blind, sham-controlled RCT with a 12-week blinded period; published peer-reviewed results show a high rate of implant success and low rates of adverse events, but do not report additional outcomes. The manufacturer's IFU reports statistical superiority of implantable VNS over sham for the prespecified primary responder endpoint, ACR20, but no significant differences on secondary clinical and functional outcomes (DAS28, The Clinical Disease Activity Index [CDAI], and Health Assessment Questionnaire Disability Index [HAQ-DI]). Safety across studies was acceptable, with mostly mild stimulation-related events and infrequent surgery-related complications. Evidence for implantable VNS remains limited to a small feasibility RCT that was not powered for efficacy, as well as a single pivotal, sham-controlled trial with outcome assessment only available in manufacturer documents, which has not yet been peer-

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

reviewed. Overall, the certainty of evidence for RA remains limited, and an additional large, peer-reviewed RCT with longer blinded follow-up is warranted. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have other neurologic conditions (e.g., essential tremors, headache, fibromyalgia, tinnitus, autism) who receive VNS, the evidence includes case series. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Case series are insufficient to draw conclusions regarding efficacy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Transcutaneous Vagus Nerve Stimulation

For individuals with cluster headaches who receive transcutaneous VNS (tVNS; also referred to as noninvasive VNS [nVNS]) to prevent cluster headaches, the evidence includes 1 RCT. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. One RCT for prevention of cluster headaches showed a reduction in headache frequency but did not include a sham treatment group. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with cluster headaches who receive nVNS to treat acute cluster headache, the evidence includes RCTs. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. The ACT1 and ACT2 RCTs compared nVNS to sham for treatment of acute cluster headaches in patients including both chronic and episodic cluster headache. In ACT1, there was no statistically significant difference in the overall population in the proportion of patients with pain score of 0 or 1 at 15 minutes into the first attack and no difference in the proportion of patients who were pain-free at 15 minutes in 50% or more of the attacks. In the episodic cluster headache subgroup (n=85) both outcomes were statistically significant favoring nVNS although the interaction p-value was not reported. In ACT2, the proportion of attacks with pain intensity score of 0 or 1 at 30 minutes was higher for nVNS in the overall population (43% vs. 28%, p=.05) while the proportion of attacks that were pain-free at 15 minutes was similar in the 2 treatment groups in the overall population (14% vs. 12%). However, a statistically significantly higher proportion of attacks in the episodic subgroup (n=27) were pain-free at 15 minutes in the nVNS group compared to sham (48% vs. 6%, p<.01). These studies suggest that people with episodic and chronic cluster headaches may respond differently to acute treatment with nVNS. Studies designed to focus on episodic cluster headache are needed. Quality of life and functional outcomes have not been reported. Treatment periods ranged from only 2 weeks to 1 month with extended open-label follow-up of up to 3 months. There are few adverse events of nVNS and they are mild and transient. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with migraine headaches who receive nVNS to treat acute migraine headaches, the evidence includes 1 RCT. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. One RCT has evaluated nVNS for acute treatment of migraine with nVNS in 248 patients with episodic migraine with/without aura. There was not a statistically significant difference in the primary outcome of the proportion of participants who were pain-free without using rescue medication at 120 minutes (30% vs. 20%; p=.07). However, the nVNS group had a higher proportion of patients with decrease in pain from moderate or

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

severe to mild or no pain at 120 minutes (41% vs. 28%; $p=.03$) and a higher proportion of patients who were pain-free at 120 minutes for 50% or more of their attacks (32% vs. 18%; $p=.02$). There are few adverse events of nVNS and they are mild and transient. Quality of life and functional outcomes were not reported, and the double-blind treatment period was 4 weeks with an additional 4 weeks of open-label treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with chronic migraine headaches who receive nVNS to prevent migraine headaches, the evidence includes 3 RCTs. Relevant outcomes are symptoms, change in disease status, quality of life and functional outcomes. The EVENT RCT was a feasibility study of prevention of migraine that was not powered to detect differences in efficacy outcomes. It does not demonstrate the efficacy of nVNS for prevention of migraine. The PREMIUM RCT was a phase 3, multicenter, sham-controlled RCT including 341 randomized participants with a 12-week double-blind treatment period. The results of PREMIUM demonstrated that nVNS was not statistically significantly superior to sham with respect to the outcomes of reduction of at least 50% in migraine days from baseline to the last 4 weeks, reduction in number of migraine days from baseline to the last 4 weeks, or acute medication days. The PREMIUM II trial was a multicenter, sham-controlled RCT including 231 randomized participants with a 12-week double-blind treatment period. The trial was terminated early due to the COVID-19 pandemic and results were based on a modified intention-to-treat population that included 113 total participants. Results demonstrated that treatment with nVNS was not statistically significantly superior to sham with respect to the primary outcome of reduction in the number of migraine days per month during weeks 9 through 12, nor other outcomes such as mean change in the number of headache days or acute medication days. However, the percentage of patients with at least a 50% reduction in the number of migraine days was significantly greater in the nVNS group than in the sham group. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have other neurologic, psychiatric, or metabolic disorders (e.g., epilepsy, depression, schizophrenia, noncluster headache, impaired glucose tolerance, fibromyalgia, stroke) who receive tVNS, the evidence includes RCTs, systematic reviews of these RCTs, and case series for some of the conditions. Relevant outcomes are symptoms, change in disease status, and functional outcomes. The RCTs are all small and have various methodologic problems. None showed definitive efficacy of tVNS in improving patient outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Peripheral Nerve Stimulators for Neuropathic Pain

For individuals who have peripheral, neuropathic, chronic pain who receive peripheral nerve stimulation (PNS), the evidence includes several randomized controlled trials (RCTs). Relevant outcomes are symptoms, medication use, and quality of life. Statistically significant differences in responder rates were reported in the RCTs ranging from 38% to 88% in the treatment groups and 0% to 24% in the control groups. Overall limitations of the current evidence includes small sample sizes, heterogeneous patient populations, high attrition rates, and lack of long-term follow-up data. Additional evidence from RCTs with larger sample sizes and longer durations of

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

comparative data are necessary to assess the efficacy and durability of PNS. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Restorative Neurostimulation Therapy

For individuals who have chronic pain conditions including low back pain who receive restorative neurostimulation therapy (ReActiv8), the evidence includes 1 sham-controlled RCT (N = 204), 1 open-label RCT (N=203), 1 prospective single-arm trial (N = 53), and a case series (N = 44). Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. In the sham-controlled RCT, there was no difference between groups on the primary endpoint of treatment response at 120 days, defined as the composite of 30% or greater reduction in VAS and no increase in pain medications (57.1% intervention vs 46.6% sham; $p = .1377$). Prespecified secondary analyses of primary outcome data favored the intervention group, but clinical significance is unclear. An uncontrolled follow-up phase of the RCT reported continued improvement in pain scores through 3 years but results are at high risk of bias due to lack of a control group and high attrition. The open-label RCT showed statistically significant improvements in the treatment arm compared to the control arm in the primary and secondary outcomes. However, limitations included lack of blinding, imbalance in baseline depression between treatment and control arms, and greater clinical contact than standard management protocols in the treatment arm. Nonrandomized studies are limited by lack of blinding, no sham control, high attrition, and small sample sizes. Additional evidence from longer-term sham controlled RCTs is needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

DEFINITIONS

EPILEPSY is a group of neurologic disorders characterized by recurrent episodes of convulsive seizures, sensory disturbances, abnormal behavior, loss of consciousness, or all of these. Common to all types of epilepsy is an uncontrolled electrical discharge from the nerve cells of the cerebral cortex.

PARTIAL ONSET SEIZURES refers to seizures that have a discrete focal onset. There are three subtypes of partial onset seizures:

- Simple partial seizures: these do not involve alteration of consciousness but may have observable motor components or may solely be a subjective sensory or emotional phenomenon.
- Complex partial seizures: these are partial-onset seizures that involve an alteration of consciousness.
- Complex partial seizures, secondarily generalized: These are partial-onset seizures that progress to involve both sides of the brain and result in a complete loss of consciousness.

VAGUS NERVE refers to either one of the longest pair of cranial nerves mainly responsible for parasympathetic control over the heart and many other internal organs, including thoracic and abdominal viscera.

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

DISCLAIMER

Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.

CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational; therefore, not covered: Non-implantable Vagus Nerve Stimulator and Implantable VNS for conditions other than medically refractory seizures:

Procedure Codes							
E0735	0908T	0909T	0910T	0911T	0912T	64999	

Investigational; therefore, not covered: Implantable Peripheral Nerve Stimulator

Procedure Codes							
64555	64575	64585	64590	64595	64596	64597	64598
64999	A4438						

Covered when medically necessary: Vagus nerve stimulator to treat medically refractory seizures:

Procedure Codes							
61885	61886	64553	64568	64569	64570	95976	95977

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

ICD-10-CM Diagnosis Codes	Description
G40.011	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus
G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
G40.119	Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.411	Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.419	Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.803	Other epilepsy, intractable, with status epilepticus
G40.804	Other epilepsy, intractable, without status epilepticus
G40.813	Lennox-Gastaut syndrome, intractable, with status epilepticus
G40.814	Lennox-Gastaut syndrome, intractable, without status epilepticus
G40.823	Epileptic spasms, intractable, with status epilepticus
G40.824	Epileptic spasms, intractable, without status epilepticus
G40.843	KCNQ2-related epilepsy, intractable, with status epilepticus
G40.844	KCNQ2-related epilepsy, intractable, without status epilepticus
G40.911	Epilepsy, unspecified, intractable, with status epilepticus
G40.919	Epilepsy, unspecified, intractable, without status epilepticus

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

ICD-10-CM Diagnosis Codes	Description
G40.A11	Absence epileptic syndrome, intractable, with status epilepticus
G40.A19	Absence epileptic syndrome, intractable, without status epilepticus
G40.C11	Lafora progressive myoclonus epilepsy, intractable, with status epilepticus
G40.C19	Lafora progressive myoclonus epilepsy, intractable, without status epilepticus
Z45.42	Encounter for adjustment and management of neuropacemaker (brain) (peripheral nerve) (spinal cord)
Z45.49	Encounter for adjustment and management of other implanted nervous system device
Z46.2	Encounter for fitting and adjustment of other devices related to nervous system and special senses

Covered when Medically Necessary when billed with an allowed surgery:

Procedure Codes							
C1767	C1778	C1816	C1820	C1827	C1883	C1897	L8678
L8679	L8680	L8681	L8682	L8683	L8685	L8686	L8687
L8688	L8689	L8695	95970	95971	95972		

REFERENCES

Vagus Nerve Stimulation

1. Panebianco M, Rigby A, Weston J, et al. Vagus nerve stimulation for partial seizures. *Cochrane Database Syst Rev.* Apr 03 2015; 2015(4): CD002896. PMID 25835947
2. Panebianco M, Rigby A, Marson AG. Vagus nerve stimulation for focal seizures. *Cochrane Database Syst Rev.* Jul 14 2022; 7(7): CD002896. PMID 35833911
3. Englot DJ, Chang EF, Augustine KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. *J Neurosurg.* Dec 2011; 115(6): 1248-55. PMID 21838505
4. Ben-Menachem E, Hellström K, Waldton C, et al. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. *Neurology.* Apr 12 1999; 52(6): 1265-7. PMID 10214754
5. Parker AP, Polkey CE, Binnie CD, et al. Vagal nerve stimulation in epileptic encephalopathies. *Pediatrics.* Apr 1999; 103(4 Pt 1): 778-82. PMID 10103302
6. Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group. *Neurology.* Apr 22 1999; 52(7): 1510-2. PMID 10227649

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

7. DeGiorgio C, Heck C, Bunch S, et al. Vagus nerve stimulation for epilepsy: randomized comparison of three stimulation paradigms. *Neurology*. Jul 26 2005; 65(2): 317-9. PMID 16043810
8. Chavel SM, Westerveld M, Spencer S. Long-term outcome of vagus nerve stimulation for refractory partial epilepsy. *Epilepsy Behav*. Jun 2003; 4(3): 302-9. PMID 12791333
9. Vonck K, Boon P, D'Havé M, et al. Long-term results of vagus nerve stimulation in refractory epilepsy. *Seizure*. Sep 1999; 8(6): 328-34. PMID 10512772
10. Vonck K, Thadani V, Gilbert K, et al. Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. *J Clin Neurophysiol*. 2004; 21(4): 283-9. PMID 15509917
11. Majoie HJ, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in children with therapy-resistant epilepsy diagnosed as Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and cost-effectiveness. *J Clin Neurophysiol*. Sep 2001; 18(5): 419-28. PMID 11709647
12. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. *Biol Psychiatry*. Feb 15 2002; 51(4): 280-7. PMID 11958778
13. Huf RL, Mamelak A, Kneedy-Cayem K. Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. *Epilepsy Behav*. May 2005; 6(3): 417-23. PMID 15820352
14. Kang HC, Hwang YS, Kim DS, et al. Vagus nerve stimulation in pediatric intractable epilepsy: a Korean bicentric study. *Acta Neurochir Suppl*. 2006; 99: 93-6. PMID 17370772
15. Ardesch JJ, Buschman HP, Wagener-Schimmel LJ, et al. Vagus nerve stimulation for medically refractory epilepsy: a long-term follow-up study. *Seizure*. Oct 2007; 16(7): 579-85. PMID 17543546
16. Michael JE, Wegener K, Barnes DW. Vagus nerve stimulation for intractable seizures: one year follow-up. *J Neurosci Nurs*. Dec 1993; 25(6): 362-6. PMID 8106830
17. Ben-Menachem E, Mañon-Espaillet R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. *Epilepsia*. 1994; 35(3): 616-26. PMID 8026408
18. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. *Neurology*. Jul 1998; 51(1): 48-55. PMID 9674777
19. Klinkenberg S, Aalbers MW, Vles JS, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. *Dev Med Child Neurol*. Sep 2012; 54(9): 855-61. PMID 22540141
20. Ryvlin P, Gilliam FG, Nguyen DK, et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. *Epilepsia*. Jun 2014; 55(6): 893-900. PMID 24754318
21. Englot DJ, Rolston JD, Wright CW, et al. Rates and Predictors of Seizure Freedom With Vagus Nerve Stimulation for Intractable Epilepsy. *Neurosurgery*. Sep 2016; 79(3): 345-53. PMID 26645965

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

22. García-Navarrete E, Torres CV, Gallego I, et al. Long-term results of vagal nerve stimulation for adults with medication-resistant epilepsy who have been on unchanged antiepileptic medication. *Seizure*. Jan 2013; 22(1): 9-13. PMID 23041031
23. Hornig GW, Murphy JV, Schallert G, et al. Left vagus nerve stimulation in children with refractory epilepsy: an update. *South Med J*. May 1997; 90(5): 484-8. PMID 9160063
24. Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. *J Pediatr*. May 1999; 134(5): 563-6. PMID 10228290
25. Patwardhan RV, Stong B, Bebin EM, et al. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. *Neurosurgery*. Dec 2000; 47(6): 1353-7; discussion 1357-8. PMID 11126906
26. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. *Epilepsia*. Sep 2001; 42(9): 1148-52. PMID 11580762
27. You SJ, Kang HC, Kim HD, et al. Vagus nerve stimulation in intractable childhood epilepsy: a Korean multicenter experience. *J Korean Med Sci*. Jun 2007; 22(3): 442-5. PMID 17596651
28. Cukiert A, Cukiert CM, Burattini JA, et al. A prospective long-term study on the outcome after vagus nerve stimulation at maximally tolerated current intensity in a cohort of children with refractory secondary generalized epilepsy. *Neuromodulation*. 2013; 16(6): 551-6; discussion 556. PMID 23738578
29. Healy S, Lang J, Te Water Naude J, et al. Vagal nerve stimulation in children under 12 years old with medically intractable epilepsy. *Childs Nerv Syst*. Nov 2013; 29(11): 2095-9. PMID 23681311
30. Terra VC, Furlanetti LL, Nunes AA, et al. Vagus nerve stimulation in pediatric patients: Is it really worthwhile?. *Epilepsy Behav*. Feb 2014; 31: 329-33. PMID 24210463
31. Yu C, Ramgopal S, Libenson M, et al. Outcomes of vagal nerve stimulation in a pediatric population: a single center experience. *Seizure*. Feb 2014; 23(2): 105-11. PMID 24309238
32. Maleknia P, McWilliams TD, Barkley A, et al. Postoperative seizure freedom after vagus nerve stimulator placement in children 6 years of age and younger. *J Neurosurg Pediatr*. Apr 01 2023; 31(4): 329-332. PMID 36670534
33. Daban C, Martinez-Aran A, Cruz N, et al. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. *J Affect Disord*. Sep 2008; 110(1-2): 1-15. PMID 18374988
34. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. *Biol Psychiatry*. Sep 01 2005; 58(5): 347-54. PMID 16139580
35. Food and Drug Administration. Summary of Safety and Effectiveness Data: VNS Therapy TM System. 2005; https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s050b.pdf. Accessed September 10, 2025.
36. Martín JL, Martín-Sánchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. *Eur Psychiatry*. Apr 2012; 27(3): 147-55. PMID 22137776

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

37. Berry SM, Broglio K, Bunker M, et al. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. *Med Devices (Auckl)*. 2013; 6: 17-35. PMID 23482508
38. Bajbouj M, Merkl A, Schlaepfer TE, et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. *J Clin Psychopharmacol*. Jun 2010; 30(3): 273-81. PMID 20473062
39. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. *Brain Stimul*. Jul 2013; 6(4): 631-40. PMID 23122916
40. Bottomley JM, LeReun C, Diamantopoulos A, et al. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: A systematic review and meta-analysis. *Compr Psychiatry*. Dec 12 2019; 98: 152156. PMID 31978785
41. Conway CR, Aaronson ST, Sackeim HA, et al. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. *Brain Stimul*. 2025; 18(3): 676-689. PMID 39706521
42. Rush AJ, Conway CR, Aaronson ST, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. *Brain Stimul*. 2025; 18(3): 690-700. PMID 39701918
43. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. *Biol Psychiatry*. Sep 01 2005; 58(5): 364-73. PMID 16139582
44. De Ferrari GM, Crijns HJ, Borggreffe M, et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. *Eur Heart J*. Apr 2011; 32(7): 847-55. PMID 21030409
45. Aaronson ST, Sears P, Ruvuna F, et al. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. *Am J Psychiatry*. Jul 01 2017; 174(7): 640-648. PMID 28359201
46. McAllister-Williams RH, Sousa S, Kumar A, et al. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. *Int J Bipolar Disord*. May 02 2020; 8(1): 13. PMID 32358769
47. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. *Biol Psychiatry*. Feb 15 2000; 47(4): 276-86. PMID 10686262
48. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. *Neuropsychopharmacology*. Nov 2001; 25(5): 713-28. PMID 11682255
49. Marangell LB, Suppes T, Zboyan HA, et al. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. *J Clin Psychiatry*. Feb 2008; 69(2): 183-9. PMID 18211128

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

50. Tisi G, Franzini A, Messina G, et al. Vagus nerve stimulation therapy in treatment-resistant depression: a series report. *Psychiatry Clin Neurosci*. Aug 2014; 68(8): 606-11. PMID 25215365
51. Sant'Anna LB, Couceiro SLM, Ferreira EA, et al. Vagal Neuromodulation in Chronic Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. *Front Cardiovasc Med*. 2021; 8: 766676. PMID 34901227
52. Premchand RK, Sharma K, Mittal S, et al. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. *J Card Fail*. Nov 2014; 20(11): 808-16. PMID 25187002
53. Nearing BD, Libbus I, Carlson GM, et al. Chronic vagus nerve stimulation is associated with multi-year improvement in intrinsic heart rate recovery and left ventricular ejection fraction in ANTHEM-HF. *Clin Auton Res*. Jun 2021; 31(3): 453-462. PMID 33590355
54. Kumar HU, Nearing BD, Mittal S, et al. Autonomic regulation therapy in chronic heart failure with preserved/mildly reduced ejection fraction: ANTHEM-HFpEF study results. *Int J Cardiol*. Jun 15 2023; 381: 37-44. PMID 36934987
55. Ramos-Castaneda JA, Barreto-Cortes CF, Losada-Floriano D, et al. Efficacy and Safety of Vagus Nerve Stimulation on Upper Limb Motor Recovery After Stroke. A Systematic Review and Meta-Analysis. *Front Neurol*. 2022; 13: 889953. PMID 35847207
56. Dawson J, Pierce D, Dixit A, et al. Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. *Stroke*. Jan 2016; 47(1): 143-50. PMID 26645257
57. Dawson J, Liu CY, Francisco GE, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. *Lancet*. Apr 24 2021; 397(10284): 1545-1553. PMID 33894832
58. Kimberley TJ, Pierce D, Prudente CN, et al. Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Chronic Stroke. *Stroke*. Nov 2018; 49(11): 2789-2792. PMID 30355189
59. Lange G, Janal MN, Maniker A, et al. Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial. *Pain Med*. Sep 2011; 12(9): 1406-13. PMID 21812908
60. De Ridder D, Vanneste S, Engineer ND, et al. Safety and efficacy of vagus nerve stimulation paired with tones for the treatment of tinnitus: a case series. *Neuromodulation*. Feb 2014; 17(2): 170-9. PMID 24255953
61. Engineer CT, Hays SA, Kilgard MP. Vagus nerve stimulation as a potential adjuvant to behavioral therapy for autism and other neurodevelopmental disorders. *J Neurodev Disord*. 2017; 9: 20. PMID 28690686
62. International Headache Society. *International Classification of Headache Disorders*. 2018; <https://www.ichd-3.org>. Accessed September 11, 2025.
63. Jokic M, Lee C, Holubowich C, et al. Noninvasive Vagus Nerve Stimulation for Cluster Headache and Migraine: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2025; 25(2): 1-177. PMID 40496978

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

64. Gaul C, Diener HC, Silver N, et al. Non-invasive vagus nerve stimulation for PREvention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. *Cephalalgia*. May 2016; 36(6): 534-46. PMID 26391457
65. Gaul C, Magis D, Liebner E, et al. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. *J Headache Pain*. Dec 2017; 18(1): 22. PMID 28197844
66. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. *Cephalalgia*. Jan 2012; 32(1): 6-38. PMID 22384463
67. Silberstein SD, Mechtler LL, Kudrow DB, et al. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. *Headache*. Sep 2016; 56(8): 1317-32. PMID 27593728
68. Goadsby PJ, de Coo IF, Silver N, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. *Cephalalgia*. Apr 2018; 38(5): 959-969. PMID 29231763
69. de Coo IF, Marin JC, Silberstein SD, et al. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. *Cephalalgia*. Jul 2019; 39(8): 967-977. PMID 31246132
70. Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. *Neurology*. Jul 24 2018; 91(4): e364-e373. PMID 29907608
71. Grazzi L, Tassorelli C, de Tommaso M, et al. Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. *J Headache Pain*. Oct 19 2018; 19(1): 98. PMID 30340460
72. Martelletti P, Barbanti P, Grazzi L, et al. Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. *J Headache Pain*. Nov 01 2018; 19(1): 101. PMID 30382909
73. Trimboli M, Al-Kaisy A, Andreou AP, et al. Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: A real-world experience. *Cephalalgia*. Jun 2018; 38(7): 1276-1285. PMID 28899205
74. Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. *Neurology*. Aug 02 2016; 87(5): 529-38. PMID 27412146
75. Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. *Cephalalgia*. Oct 2019; 39(12): 1475-1487. PMID 31522546
76. Najib U, Smith T, Hindiyeh N, et al. Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. *Cephalalgia*. Jun 2022; 42(7): 560-569. PMID 35001643

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

77. Grazzi L, Egeo G, Calhoun AH, et al. Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. *J Headache Pain*. Dec 2016; 17(1): 91. PMID 27699586
78. Kinfe TM, Pinte B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. *J Headache Pain*. 2015; 16: 101. PMID 26631234
79. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. *Arthritis Rheum*. Mar 15 2007; 57(2): 193-202. PMID 17330293
80. Curtis JR, Yang S, Chen L, et al. Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. *Arthritis Care Res (Hoboken)*. Oct 2015; 67(10): 1345-53. PMID 25988705
81. Johnson TM, Michaud K, England BR. Measures of rheumatoid arthritis disease activity. *Arthritis Care Res*. 2020;72(suppl 10):4-26. doi:10.1002/acr.24336.
82. Strand V, van Vollenhoven RF, Lee EB, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. *Rheumatology (Oxford)*. Jun 2016; 55(6): 1031-41. PMID 26929445
83. Genovese MC, Gaylis NB, Sikes D, et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. *Lancet Rheumatol*. Sep 2020; 2(9): e527-e538. PMID 38273617
84. Peterson D, Van Poppel M, Boling W, et al. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. *Bioelectron Med*. Mar 13 2024; 10(1): 8. PMID 38475923
85. SetPoint Medical. SetPoint System: Surgeon Instructions for Use. https://setpointmedical.com/wp-content/uploads/DWG_65154_Surgeon_IFUv2.pdf. Accessed October 1, 2025.
86. Aihua L, Lu S, Liping L, et al. A controlled trial of transcutaneous vagus nerve stimulation for the treatment of pharmacoresistant epilepsy. *Epilepsy Behav*. Oct 2014; 39: 105-10. PMID 25240121
87. Bauer S, Baier H, Baumgartner C, et al. Transcutaneous Vagus Nerve Stimulation (tvNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02). *Brain Stimul*. 2016; 9(3): 356-363. PMID 27033012
88. Rong P, Liu A, Zhang J, et al. Transcutaneous vagus nerve stimulation for refractory epilepsy: a randomized controlled trial. *Clin Sci (Lond)*. Apr 01 2014. PMID 24684603
89. Wu K, Wang Z, Zhang Y, et al. Transcutaneous vagus nerve stimulation for the treatment of drug-resistant epilepsy: a meta-analysis and systematic review. *ANZ J Surg*. Apr 2020; 90(4): 467-471. PMID 32052569
90. Yang H, Shi W, Fan J, et al. Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial. *Neurotherapeutics*. Apr 2023; 20(3): 870-880. PMID 36995682

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

91. Shi J, Lu D, Wei P, et al. Comparative Efficacy of Neuromodulatory Strategies for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis. *World Neurosurg.* Jan 2025; 193: 373-396. PMID 39321920
92. Hasan A, Wolff-Menzler C, Pfeiffer S, et al. Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. *Eur Arch Psychiatry Clin Neurosci.* Oct 2015; 265(7): 589-600. PMID 26210303
93. Shiozawa P, Silva ME, Carvalho TC, et al. Transcutaneous vagus and trigeminal nerve stimulation for neuropsychiatric disorders: a systematic review. *Arq Neuropsiquiatr.* Jul 2014; 72(7): 542-7. PMID 25054988
94. Hein E, Nowak M, Kiess O, et al. Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. *J Neural Transm (Vienna).* May 2013; 120(5): 821-7. PMID 23117749
95. Huang F, Dong J, Kong J, et al. Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study. *BMC Complement Altern Med.* Jun 26 2014; 14: 203. PMID 24968966
96. Wu D, Ma J, Zhang L, et al. Effect and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Recovery of Upper Limb Motor Function in Subacute Ischemic Stroke Patients: A Randomized Pilot Study. *Neural Plast.* 2020; 2020: 8841752. PMID 32802039
97. Kutlu N, Özden AV, Alptekin HK, et al. The Impact of Auricular Vagus Nerve Stimulation on Pain and Life Quality in Patients with Fibromyalgia Syndrome. *Biomed Res Int.* 2020; 2020: 8656218. PMID 32190684
98. Fisher RS, Handforth A. Reassessment: vagus nerve stimulation for epilepsy [RETIRED]: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* Sep 11 1999; 53(4): 666-9. PMID 10489023
99. Morris GL, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* Oct 15 2013; 81(16): 1453-9. PMID 23986299
100. American Psychiatric Association, Work Group on Major Depressive Disorder, Gelenberg AJ, et al. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Third Edition. 2010; 3rd ed.:https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/md_d.pdf. Accessed September 11, 2025.
101. National Institute for Health and Care Excellence. Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552). 2016; <https://www.nice.org.uk/guidance/ipg552>. Accessed September 12, 2025.
102. National Institute for Health and Care Excellence. gammaCore for cluster headache (MIB162). 2018. <https://www.nice.org.uk/advice/mib162>. Accessed September 13, 2025.
103. National Institute for Health and Care Excellence. Medical technologies guidance [MTG46]: gammaCore for cluster headache. December 2019. <https://www.nice.org.uk/guidance/MTG46>. Accessed September 10, 2025.
104. National Institute for Health and Care Excellence. Implanted vagus nerve stimulation for treatment-resistant depression - Interventional Procedures Guidance (IPG679). 2020;

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

<https://www.nice.org.uk/guidance/ipg679/chapter/1-Recommendations>. Accessed September 11, 2025.

105. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for VAGUS Nerve Stimulation (VNS) (160.18). 2019; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=230>. Accessed September 10, 2025.
106. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Vagus Nerve Stimulation for Treatment Resistant Depression (TRD) (CAG-00313R2). February 2019; <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=292&NCDId=230>. Accessed September 11, 2025.
107. Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Bolland E, Lux L, Weber RP, Randolph C, Bann C, Coker-Schwimmer E, Viswanathan M, Lohr KN. Definition of Treatment-Resistant Depression in the Medicare Population [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Feb 9. PMID: 30260611.
108. Centers for Medicare & Medicaid Services. Coverage with Evidence Development for Vagus Nerve Stimulation for Treatment Resistant Depression. 2024. <https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/VNS>. Accessed September 12, 2025.
109. Conway CR, Olin B, Aaronson ST, et al. A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A novel design for a novel treatment. *Contemp Clin Trials*. Aug 2020; 95: 106066. PMID 32569757

Peripheral Nerve Stimulation

1. Hardt J, Jacobsen C, Goldberg J, et al. Prevalence of chronic pain in a representative sample in the United States. *Pain Med*. Oct 2008; 9(7): 803-12. PMID 18346058
2. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain*. Jan 2005; 113(1-2): 9-19. PMID 15621359
3. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*. Feb 2008; 9(2): 105-21. PMID 18055266
4. Char S, Jin MY, Francio VT, et al. Implantable Peripheral Nerve Stimulation for Peripheral Neuropathic Pain: A Systematic Review of Prospective Studies. *Biomedicines*. Oct 17 2022; 10(10). PMID 36289867
5. Deer T, Pope J, Benyamin R, et al. Prospective, Multicenter, Randomized, Double-Blinded, Partial Crossover Study to Assess the Safety and Efficacy of the Novel Neuromodulation System in the Treatment of Patients With Chronic Pain of Peripheral Nerve Origin. *Neuromodulation*. Jan 2016; 19(1): 91-100. PMID 26799373
6. Gilmore C, Ilfeld B, Rosenow J, et al. Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial. *Reg Anesth Pain Med*. Jun 2019; 44(6): 637-645. PMID 30954936
7. Gilmore CA, Ilfeld BM, Rosenow JM, et al. Percutaneous 60-day peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

- month follow-up of a randomized, double-blind, placebo-controlled trial. *Reg Anesth Pain Med*. Nov 17 2019. PMID 31740443
8. Ilfeld BM, Plunkett A, Vijjeswarapu AM, et al. Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Pain: A Randomized, Sham-controlled Pilot Study. *Anesthesiology*. Jul 01 2021; 135(1): 95-110. PMID 33856424
 9. Goree JH, Grant SA, Dickerson DM, et al. Randomized Placebo-Controlled Trial of 60-Day Percutaneous Peripheral Nerve Stimulation Treatment Indicates Relief of Persistent Postoperative Pain, and Improved Function After Knee Replacement. *Neuromodulation*. Jul 2024; 27(5): 847-861. PMID 38739062
 10. Hatheway J, Hersel A, Song J, et al. Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 3-month and 6-month results from the COMFORT-randomised controlled trial. *Reg Anesth Pain Med*. May 31 2024. PMID 38821535
 11. Hatheway J, Hersel A, Engle M, et al. Clinical study of a micro-implantable pulse generator for the treatment of peripheral neuropathic pain: 12-month results from the COMFORT-randomized controlled trial. *Reg Anesth Pain Med*. Nov 20 2024. PMID 39572166
 12. Langford B, D'Souza RS, Pingree M, et al. Treatment of Ulnar Neuropathic Pain with Peripheral Nerve Stimulation: Two Case Reports. *Pain Med*. May 02 2023; 24(5): 566-569. PMID 36271859
 13. Oswald J, Shahi V, Chakravarthy KV. Prospective case series on the use of peripheral nerve stimulation for focal mononeuropathy treatment. *Pain Manag*. Nov 2019; 9(6): 551-558. PMID 31686589
 14. Deer TR, Levy RM, Rosenfeld EL. Prospective clinical study of a new implantable peripheral nerve stimulation device to treat chronic pain. *Clin J Pain*. Jun 2010; 26(5): 359-72. PMID 20473041
 15. Luna D, Hettie G, Pirrotta L, et al. Real-world long-term outcomes of peripheral nerve stimulation: a prospective observational study. *Pain Manag*. Jan 2025; 15(1): 37-44. PMID 39834252
 16. Strand N, D'Souza RS, Hagedorn JM, et al. Evidence-Based Clinical Guidelines from the American Society of Pain and Neuroscience for the Use of Implantable Peripheral Nerve Stimulation in the Treatment of Chronic Pain. *J Pain Res*. 2022; 15: 2483-2504. PMID 36039168
 17. Centers for Medicare & Medicaid. National Coverage Determination (NCD) for Peripheral Nerve Stimulation (L34328). 2019; <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=34328>. Accessed June 13, 2025.
 18. Gilligan C, Volschenk W, Russo M, et al. Long-Term Outcomes of Restorative Neurostimulation in Patients With Refractory Chronic Low Back Pain Secondary to Multifidus Dysfunction: Two-Year Results of the ReActiv8-B Pivotal Trial. *Neuromodulation*. Jan 2023; 26(1): 87-97. PMID 35088722
 19. Gilligan C, Volschenk W, Russo M, et al. Three-Year Durability of Restorative Neurostimulation Effectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction. *Neuromodulation*. Jan 2023; 26(1): 98-108. PMID 36175320

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

20. Gilligan C, Volschenk W, Russo M, et al. Five-Year Longitudinal Follow-Up of Restorative Neurostimulation Shows Durability of Effectiveness in Patients With Refractory Chronic Low Back Pain Associated With Multifidus Muscle Dysfunction. *Neuromodulation*. 2024;27(5):930-943. doi:10.1016/j.neurom.2024.01.006
21. Schwab F, Mekhail N, Patel KV, et al. Restorative Neurostimulation Therapy Compared to Optimal Medical Management: A Randomized Evaluation (RESTORE) for the Treatment of Chronic Mechanical Low Back Pain due to Multifidus Dysfunction. *Pain Ther*. Feb 2025; 14(1): 401-423. PMID 39812968
22. Deckers K, De Smedt K, Mitchell B, et al. New Therapy for Refractory Chronic Mechanical Low Back Pain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial. *Neuromodulation*. Jan 2018; 21(1): 48-55. PMID 29244235
23. Thomson S, Chawla R, Love-Jones S, et al. Restorative Neurostimulation for Chronic Mechanical Low Back Pain: Results from a Prospective Multi-centre Longitudinal Cohort. *Pain Ther*. Dec 2021; 10(2): 1451-1465. PMID 34478115
24. Mitchell B, Deckers K, De Smedt K, et al. Durability of the Therapeutic Effect of Restorative Neurostimulation for Refractory Chronic Low Back Pain. *Neuromodulation*. Aug 2021; 24(6): 1024-1032. PMID 34242440
25. Ardeshiri A, Shaffrey C, Stein KP, et al. Real-World Evidence for Restorative Neurostimulation in Chronic Low Back Pain-a Consecutive Cohort Study. *World Neurosurg*. Dec 2022; 168: e253-e259. PMID 36184040
26. National Institute for Health and Care Excellence. 2022 Neurostimulation of lumbar muscles for refractory nonspecific chronic low back pain: Interventional Procedures Guidance. <https://www.nice.org.uk/guidance/ipg739>.
27. Lorio M, Lewandrowski KU, Coric D, Phillips F, Shaffrey CI. International Society for the Advancement of Spine Surgery Statement: Restorative Neurostimulation for Chronic Mechanical Low Back Pain Resulting From Neuromuscular Instability. *Int J Spine Surg*. 2023;17(5):728-750. doi:10.14444/8525
28. Sayed D, Grider J, Strand N, et al. The American Society of Pain and Neuroscience (ASPN) Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain [published correction appears in *J Pain Res*. 2022 Dec 24;15:4075-4076. doi: 10.2147/JPR.S402370]. *J Pain Res*. 2022;15:3729-3832. Published 2022 Dec 6. doi:10.2147/JPR.S386879
29. Bouche B, Manfrotto M, Rigoard P, et al. Peripheral Nerve Stimulation of Brachial Plexus Nerve Roots and Supra-Scapular Nerve for Chronic Refractory Neuropathic Pain of the Upper Limb. *Neuromodulation*. 2017;20(7):684-689. doi:10.1111/ner.12573
30. Manchikanti L, Sanapati MR, Soin A, et al. Comprehensive Evidence-Based Guidelines for Implantable Peripheral Nerve Stimulation (PNS) in the Management of Chronic Pain: From the American Society Of Interventional Pain Physicians (ASIPP). *Pain Physician*. 2024;27(S9):S115-S191.

POLICY HISTORY

MP 1.034	03/25/2020 Consensus Review. Policy statement unchanged. Variations, definitions, and references updated. Coding reviewed.
-----------------	---

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

03/19/2021 Administrative Update. Added new HCPCS code K1020.
04/01/2021 Minor Review. Added new CPT codes: 0424T, 0425T, 0426T, 0427T, 0428T, 0429T, 0430T, 0431T, 0432T, 0433T, 0434T, 0435T, 0436T. Added HCPC code C1823, added ICD-10 code G47.31, Added to policy statement. References updated and added. Description/Background and Rationale updated.
06/14/2022 Consensus Review. No change to policy statement. References, background, and rationale updated. Coding reviewed.
03/16/2023 Administrative Update. Added new HCPCS Code L8678.
07/18/2023 Consensus Review. No change to policy statement. New references.
10/11/2023 Minor Review. Added NMN statement for restorative neurostimulation therapy (ReActiv8 device). Updated background, rationale, and references. Moved K1020 to correct coding table based on our policy statement.
12/12/2023 Administrative Update. New Code Review: 33276-33288 replacing 0424T-0436T. E0735 replacing K1020. Adding 64596-64598 and 93150-93153.
03/15/2024 Administrative Update. Added New Code A4438. Effective 04/01/2024.
08/15/2024 Administrative Update. Added new ICD-10 codes. Effective 10/01/2024.
08/29/2024 Minor Review. Title change. Minor editorial refinements to VNS statements; no change to intent. Added statement to VNS that transcutaneous/non-implantable is INV. Implantable peripheral nerve stimulators are now INV. ReActiv8 went from NMN to INV. Phrenic Nerve Stimulation has been removed from this policy; phrenic nerve stimulation for CSA has been moved to MP 1.128. Added policy guidelines. Updated cross references, background, rationale, definitions, and references. Placed codes used for more than one indication into coding table titled "Covered when Medically Necessary when billed with an allowed surgery".
12/13/2024 Administrative Update. Added 0908T-0912T as part of New Code Update. Eff date 01/01/2025
06/26/2025 Administrative Update. Removed Benefit Variations Section and updated Disclaimer.
09/22/2025 Consensus Review. Updated policy guidelines, cross-references, background, rationale, and references. Added 64999 and C1827 to coding tables.
02/09/2026 Minor Review. Added rheumatoid arthritis to INV VNS statement. Updated policy guidelines, cross-references, background, rationale, and references. No changes to coding.

MEDICAL POLICY

POLICY TITLE	VAGUS NERVE AND IMPLANTABLE PERIPHERAL NERVE STIMULATORS
POLICY NUMBER	MP 1.034

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.